FDA approves Fluzakura for treatment of refractory metastatic colorectal cancer
November 9, 2023 2 minute read Add topics to email alerts Receive an email when a new article is posted Enter your email address to receive emails when new articles are posted. . ” data-action=”subscribe”> Subscribe Your request could not be processed. Please try again later. If you continue to experience […]
FDA approves Fluzakura for previously treated metastatic colorectal cancer
The Food and Drug Administration (FDA) has approved Fluzakura (fruquintinib) for the treatment of some adults with metastatic colorectal cancer (mCRC), biopharmaceutical company Takeda Pharmaceutical announced in a news release. Patients are eligible for treatment with Fluzacra, an oral targeted therapy, after treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy and anti-VEGF therapy. Patients with wild-type RAS […]